Principal

Thomas de Vlaam

Thomas was previously at Flagship Pioneering, where he was responsible for developing the science, business strategy, and intellectual property behind new platform companies.

Before joining Flagship, Thomas was founder and CEO of Amylon Therapeutics, a biotechnology startup that focused on using RNA therapeutics to treat rare neurodegenerative disease. Thomas created Amylon as a spin-out from ProQR Therapeutics, where he was previously their head of CNS innovation.

Thomas holds a B.Sc. degree in International Medicine and Global Health. His work has resulted in multiple patents and publications. Thomas was elected one of the top 10 young European biotech entrepreneurs by Labiotech, as well as one of the 30 rising leaders in life sciences by Invivo.